Investor Presentaiton

Reported EBIT margin of 28%¹ in 9M, reflecting impact from cost inflation, increased level of commercial activity and amortisation costs 9M 2022/23 EBIT margin development before special items (%) 30.8 -2.0 -0.9 0.4 -0.1 28.1 -0.2 -0.2 27.9 Reported EBIT margin 9M 21/221 A Gross margin Δ Δ Admin- A R&D- Distribution- to-sales to-sales to-sales Δ Other operating items Reported EBIT margin 9M 22/231 Currency EBIT margin effect 9M 22/23 (Constant Currencies)1 9M 2022/23 highlights Gross margin was 67%, against 69% in 9M last year • Negative impact from: input cost inflation (raw materials, energy, freight), double-digit wage inflation in Hungary and ramp-up costs in Costa Rica. Positive impact from: Atos Medical, price increases, country and product mix, operating leverage, and efficiency savings Positive FX impact on gross margin of around 10 bps Operating expenses in 9M amounted to DKK 7,065 million. Operating expenses grew 7% from last year excl. inorganic operating expenses from Atos Medical (13% incl. inorganic OPEX). Atos Medical contributed with DKK 854 million, including DKK 159 million in amortisation costs Distribution-to-sales ratio was 31%, compared to 30% last year Distribution costs were up 14% vs. last year, impacted by Atos Medical, increased sales & marketing activities and travel post COVID- 19, higher logistics costs, and continued commercial investments (Interventional Urology, consumer and digital, Atos Medical) The admin-to-sales ratio was 5%, compared to 4% last year. The R&D-to- sales ratio was 4%, on par with last year EBIT before special items was DKK 5,131 million, a 1% increase from last year. Reported EBIT margin before special items was 28% against 31% last year (positive impact of 20 bps from FX) 1 Before special items of DKK 5 million in 9M 2022/23 and DKK 435 million in 9M 2021/22. 63 Coloplast

View entire presentation